Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Amalgamated Bank

Amalgamated Bank lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,815 shares of the medical equipment provider’s stock after selling 1,670 shares during the quarter. Amalgamated Bank’s holdings in Zimmer Biomet were worth $4,538,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Chicago Partners Investment Group LLC increased its position in Zimmer Biomet by 3.3% in the 4th quarter. Chicago Partners Investment Group LLC now owns 2,894 shares of the medical equipment provider’s stock valued at $349,000 after acquiring an additional 92 shares during the period. North Star Investment Management Corp. raised its stake in shares of Zimmer Biomet by 16.6% during the first quarter. North Star Investment Management Corp. now owns 669 shares of the medical equipment provider’s stock valued at $88,000 after purchasing an additional 95 shares in the last quarter. First Bancorp Inc ME lifted its holdings in Zimmer Biomet by 5.3% in the first quarter. First Bancorp Inc ME now owns 1,970 shares of the medical equipment provider’s stock worth $260,000 after purchasing an additional 100 shares during the period. Ballentine Partners LLC grew its position in Zimmer Biomet by 2.6% in the 1st quarter. Ballentine Partners LLC now owns 3,957 shares of the medical equipment provider’s stock valued at $522,000 after buying an additional 100 shares in the last quarter. Finally, Romano Brothers AND Company increased its stake in Zimmer Biomet by 1.1% during the 1st quarter. Romano Brothers AND Company now owns 9,514 shares of the medical equipment provider’s stock valued at $1,256,000 after buying an additional 100 shares during the period. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ZBH. Truist Financial reaffirmed a “hold” rating and issued a $112.00 price target (down from $117.00) on shares of Zimmer Biomet in a research note on Friday, September 13th. Robert W. Baird decreased their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Royal Bank of Canada dropped their price objective on Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Barclays decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. Finally, Piper Sandler cut shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $140.00 to $115.00 in a research report on Monday, July 1st. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $125.17.

Zimmer Biomet Trading Up 0.1 %

Zimmer Biomet stock opened at $106.42 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $133.90. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The stock has a market cap of $21.89 billion, a P/E ratio of 23.03, a P/E/G ratio of 1.96 and a beta of 1.02. The company’s fifty day simple moving average is $109.83 and its 200-day simple moving average is $115.46.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.02. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.94 billion. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.82 earnings per share. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.02 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.90%. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.